|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Preparation and pharmaceutical/pharmacokinetic characterization of liposomes and nanoparticles loaded with epirubicin显示文摘 | Leucuta SE Achim M Risca R | | 0，，05： | 1 |
| 2 | Oxprenolol-loaded bioadhesive micmspheres: preparation and in vitro/in vivo characterization 显示文摘 | PREDA M LEUCUTA S E | 2003 | Microencapsulation2003，20，6： | 1 |
| 3 | Relationship between cachexia and perineural invasion in pancreatic adenocarcinoma显示文摘BACKGROUND Cachexia is responsible for the low quality of life in pancreatic adenocarcinoma(PDAC).The rapid disease progression and patient deterioration seems related to perineural invasion,but the relationship between cachexia and perineural invasion for the evolution of the disease has been rarely studied.As perineural invasion is difficult to be highlighted,a biomarker such as the neurotrophic factor Midkine(MK)which promotes the neuronal differentiation and the cell migration could be helpful.Also,Activin(ACV)has been described as cachexia related to PDAC.However,their role for assessing and predicting the disease course in daily practice is not known.AIM To assess the relationship between perineural invasion and cachexia and their biomarkers,MK and ACV,respectively,and their prognostic value.METHODS This study included prospectively enrolled patients with proven adenocarcinoma and a matched group of controls without any malignancies.Patients with other causes of malnutrition were excluded.The plasma levels of ACV and MK were analyzed using western blotting and were correlated with the clinicopathological features and survival data.These results were validated by immunohistochemical analyses of the pancreatic tumor tissue of the patients included in the study and a supplementary group of surgically resected specimens from patients with a benign disease.RESULTS The study comprised 114 patients with PDAC,125 controls and a supplementary group of 14 benign pancreatic tissue samples.ACV and MK were both overexpressed more frequently in the plasma of patients with PDAC than in the controls(63% vs 32% for ACV,P<0.001;47%vs 16%for MK,P<0.001),with similar levels in pancreatic tissue the MK protein expression was closely related to the advanced clinical stage(P=0.006),the presence of metastasis(P=0.04),perineural invasion(P=0.03)and diabetes(P=0.002),but with no influence on survival.No correlation between clinicopathological factors and ACV expression was noted.Cachexia,present in 19%of patients,was unrelated to ACV or MK level.Higher ACV expression was associated with a shorter survival(P=0.008).CONCLUSION The MK was a biomarker of perineural invasion,associated with tumor stage and diabetes,but without prognostic value as ACV.Cachexia was unrelated to perineural invasion,ACV level or survival. | Livia Petrusel Ioana Rusu Daniel Corneliu Leucuta Radu Seicean Ramona Suharoschi Paula Zamfir Andrada Seicean | 2019 | World Journal of Gastrointestinal Oncology2019，11，12： | 1 |
| 4 | Controlled release of nifedipine from gelatin microspheres and microcapsu - les: in vitro kinetics and pharmacokinetics in man 显示文摘 | Leucuta SE | 1990 | J microencapsulation1990，7，2： | 1 |
| 5 | Determination of fluoxetine and its N-desmethyl metabolite in human plasma by high -performance liquid chromatography 显示文摘 | Vlase L Imre S Leucuta S | 2005 | Talanta2005，66，： | 1 |
| 6 | Pharmacokinetic interaction study between ranitidine and metoclopramide 显示文摘 | Leucuta A Vlase L Farcau D | 2004 | Rom J Gastroenterol2004，13，3： | 1 |
| 7 | Nanotechnology for delivery of drugsand biomedical applications 显示文摘 | EMILIAN LEUCUTA S | 2010 | Curr Clin Pharmacol2010，5，4： | 1 |
| 8 | Pharmacokinetics and metabolic drug interactions 显示文摘 | LEUCUTA S E VLASE L V | 2006 | Curr Clin Pharmacol2006，1，1： | 1 |
| 9 | Pharmacokinetics and metabolic drug interactions显示文摘 | LEUCUTA S E VLASE L | 2006 | Current clinical pharmacology2006，1，1： | 1 |
| 10 | Determination of tramadol andO-desmethyltramadol in human plasma by high-performance liq- uid chromatography with mass spectrometry detection 显示文摘 | Vlase L Leucuta SE Imreb S | 2008 | Ta- lanta2008，75，4： | 1 |
| 11 | Pharmacokinetics and metabolic drug interactions显示文摘 | LEUCUTA SE VLASE L | 2006 | Curr Clin Pharmacol2006，1，1： | 1 |
| 12 | Optimization of propranolol hydrochloride sustained-release pellets using a factorial design显示文摘 | Bodea A Leucuta SE | 1997 | Int J Pharm1997，154，1： | 1 |
| 13 | Optimization of propranolol hydrochloride sustained-release pellets using box-behnken design and desirability function显示文摘 | BODEA A LEUCUTA SE | 1998 | Drug Dev Ind Pharm1998，24，2： | 1 |
| 14 | Determination of tramadol and O-desmethyltramadol in human plasma by high-per- formance liquid chromatography with mass spectrometry detection显示文摘 | Vlase L Leucuta SE Imre S | 2008 | Talanta2008，75，4： | 1 |
| 15 | Pharmacokinetics and metabolic drug interactions显示文摘 | Leucuta SE Vlase L | 2006 | Current Clinical Pharmacology2006，1，1： | 1 |
| 16 | Detemaination of tramadol and O- desmethyltramadol in human plasma by high-performance liquid chromatography with mass spectrometry detection显示文摘 | Vlase L Leucuta SE Imre S | 2008 | Talanta2008，75，4： | 1 |
| 17 | New HPLC-MS method for quantitative determination of apovincaminic acid in human plasma显示文摘 | VLASE L IMRE S LEUCUTA S | 2006 | J Sep Sei2006，29，3： | 1 |
| 18 | Pharmacokinetics and metabolic drug interactions 显示文摘 | LEUCUTA S E VLASE L | 2006 | Current Clini Pharm2006，1，1： | 1 |
| 19 | Pharmacokinetics and metabolic drug interactions显示文摘 | Leucuta S E Vlase L | 2006 | Curr Clin Pharmacol2006，1，1： | 1 |
| 20 | Optimization of propranolol hydrochlo- ride sustained-release pellets using a factorialdesign 显示文摘 | BODEA A LEUCUTA SE | 1997 | Int J Pharm1997，154，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员